Topic
Oxford biotech OMass announced a USD 310 million (GBP 230 million) Series C on 15 October 2026, co-led by Bain Capital Life Sciences, Forbion and Novo Holdings. Syncona's stake will be 16.1% on full drawdown.
The Cambridge microbiome drug developer announced the first close of a GBP 36 million (USD 48 million) Series C; IP Group put…
In a hospital, the handover is when one shift tells the next what changed and what to watch. Ours does the same for the business of healthcare, every weekday morning once it launches.
One email each weekday after launch. Unsubscribe at any time.